المؤلفون: Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid

المصدر: Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063Test

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, DOXORUBICIN, Population, Ipilimumab, Protein Serine-Threonine Kinases, Sunitinib/therapeutic use, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, PD-1, Antineoplastic Combined Chemotherapy Protocols, Post-hoc analysis, Sunitinib, Carcinoma, medicine, Humans, Hippo Signaling Pathway, education, Carcinoma, Renal Cell, education.field_of_study, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Nivolumab/adverse effects, medicine.disease, SYSTEMIC THERAPY, Kidney Neoplasms, Confidence interval, Kidney Neoplasms/drug therapy, Editorial Commentary, Nivolumab, 030104 developmental biology, ANTIBODY, GEMCITABINE, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, SURVIVAL, Ipilimumab/adverse effects, Immunotherapy, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ef4fae16505a538074156c51ab25aTest
https://doi.org/10.1158/1078-0432.ccr-20-2063Test

المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test

المؤلفون: Anders Overby, Morten Ladekarl, Britt Elmedal Laursen, Lone Duval, Frede Donskov

المصدر: Overby, A, Duval, L, Ladekarl, M, Laursen, B E & Donskov, F 2019, ' Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature ', Clinical Genitourinary Cancer, vol. 17, no. 1, pp. e32-e37 . https://doi.org/10.1016/j.clgc.2018.08.005Test

مصطلحات موضوعية: Oncology, Sorafenib, Male, medicine.medical_specialty, Protein Kinase Inhibitors/therapeutic use, Urology, medicine.medical_treatment, 030232 urology & nephrology, urologic and male genital diseases, Targeted therapy, Pazopanib, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, Carcinoma, medicine, Humans, Molecular Targeted Therapy, Carcinoma, Papillary/drug therapy, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, Retrospective Studies, Sunitinib, business.industry, Cancer, Middle Aged, medicine.disease, Prognosis, Primary tumor, Immunohistochemistry, Carcinoma, Papillary, Kidney Neoplasms, Survival Rate, Kidney Neoplasms/drug therapy, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Neoplasms, Unknown Primary/drug therapy, Carcinoma, Renal Cell/drug therapy, Neoplasms, Unknown Primary, Female, business, medicine.drug, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db3e8c53bbe0ed8c19f1b72df78a058Test
https://pure.au.dk/portal/da/publicationsTest/carcinoma-of-unknown-primary-site-cup-with-metastatic-renalcell-carcinoma-mrcc-histologic-and-immunohistochemical-characteristics-cupmrcc(6b394423-c717-49c5-a660-040ce867b390).html

المؤلفون: Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma

المساهمون: Hospital Universitario 12 de Octubre, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University

المصدر: CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126Test
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE

مصطلحات موضوعية: 0301 basic medicine, Anticuerpos Monoclonales, Male, Indoles, MULTICENTER, Supervivencia sin Enfermedad, urologic and male genital diseases, THERAPY, 0302 clinical medicine, Antineoplastic Agents, Immunological, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Sunitinib, Tasa de Supervivencia, Ipilimumab/administration & dosage, Masculino, Aged, 80 and over, Persona de Mediana Edad, KIDNEY CANCER, Adulto, Antibodies, Monoclonal, PHASE-III TRIAL, General Medicine, Indoles/administration & dosage, Middle Aged, OPEN-LABEL, Kidney Neoplasms, Humanos, Axitinib, Survival Rate, Kidney Neoplasms/drug therapy, Nivolumab, 030220 oncology & carcinogenesis, Antineoplásicos Inmunológicos, medicine.drug, Protocolos de Quimioterapia Combinada Antineoplásica, Adult, Risk, medicine.medical_specialty, Análisis de Supervivencia, Anciano, Urology, Ipilimumab, Riesgo, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, PAZOPANIB, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Syöpätaudit - Cancers, medicine, Carcinoma, Humans, Pyrroles, SYMPTOM INDEX, Carcinoma de Células Renales, Survival rate, Carcinoma, Renal Cell, Survival analysis, Aged, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Pyrroles/administration & dosage, UNTREATED MELANOMA, medicine.disease, Pirroles, Survival Analysis, Anciano de 80 o más Años, 1ST-LINE TREATMENT, 030104 developmental biology, Carcinoma, Renal Cell/drug therapy, Quality of Life, Calidad de Vida, INTERFERON-ALPHA, business, Neoplasias Renales

وصف الملف: application/pdf; fulltext

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4Test
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versusTest-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html

المؤلفون: Pascal Wolter, Alexandra Karadimou, Jean-Jacques Body, Patrick Schöffski, H. Van Poppel, Ludo Willems, Benoit Beuselinck, Philip R. Debruyne, Annick Rogiers, T. van Cann, R. Elaidi, Robert Paridaens, Herlinde Dumez, Joost Berkers, Evelyne Lerut

المصدر: British Journal of Cancer
British Journal of Cancer, 107 (10

مصطلحات موضوعية: Male, Cancer Research, Pathology, Diphosphonates -- administration & dosage -- adverse effects, Indoles, Phenylurea Compounds -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Targeted therapy, bone metastases, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Sunitinib, Neoplasm Metastasis, Indoles -- administration & dosage, Outcome, Bone Density Conservation Agents, Diphosphonates, Protein Kinase Inhibitors -- administration & dosage, Osteonecrosis, Bisphosphonates, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, Sorafenib, Prognosis, targeted therapy, Kidney Neoplasms, Treatment Outcome, Oncology, outcome, Female, Niacinamide -- administration & dosage -- analogs & derivatives, Tyrosine kinase, medicine.drug, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Niacinamide, medicine.medical_specialty, renal cell carcinoma, Bone Neoplasms, Osteonecrosis -- chemically induced, Disease-Free Survival, Kidney Neoplasms -- drug therapy -- pathology, Pyrroles -- administration & dosage, medicine, Carcinoma, Humans, Pyrroles, Carcinoma, Renal Cell, Protein Kinase Inhibitors, bisphosphonates, Retrospective Studies, Osteonecrosis of the jaw, business.industry, Protein-Tyrosine Kinases -- antagonists & inhibitors, Bone metastases, Phenylurea Compounds, medicine.disease, osteonecrosis of the jaw, Concomitant, Cancer research, Clinical Study, business

وصف الملف: 1 full-text file(s): application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb22c4137af4f142fa2a48d0882b042Test
https://pubmed.ncbi.nlm.nih.gov/23132391Test